INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2024

Curcumin supplementation (500 mg/d for 24 weeks) significantly reduced hepatic fat content, weight, and glycemic markers in patients with NASFL.

In a 24-week double-blind randomized trial, 80 patients with NASFL were assigned to 500 mg/day curcumin or placebo. Compared with placebo, curcumin significantly reduced controlled attenuation parameters (-17.5 dB/m; P < 0.001), body weight (-2.6 kg; P < 0.001), BMI (-1.0 kg/m2; P = 0.032), free fatty acids, triglycerides, fasting blood glucose, HbA1c, and insulin. Curcumin also decreased the Firmicutes to Bacteroidetes ratio, increased Bacteroides abundance, elevated serum deoxycholic acid and glucagon-like peptide-1, and increased TGR5 expression.

Study type
Double-blind randomized controlled trial
Who was studied
80 patients with nonalcoholic simple fatty liver (NASFL)
What was measured
Hepatic fat content (controlled attenuation parameters), body composition, gut microbiota, and bile acid metabolism

THE PAPER

Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.

He Y, Chen X, Li Y, Liang Y, Hong T, Yang J, Cao Z, Mai H, Yao J, Zhang T, Wu K, Zou J, Feng D. Am J Clin Nutr, 2024.

PubMed 38795741 ↗DOI 10.1016/j.ajcnut.2024.05.017 ↗

Diabetes & blood sugarGut & microbiomeWeight & appetiteOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.